Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 12/2008

01-12-2008 | Review Article

Sialorrhoea and Drooling in Patients with Parkinson’s Disease

Epidemiology and Management

Author: Dr Marcelo Merello

Published in: Drugs & Aging | Issue 12/2008

Login to get access

Abstract

Although often less recognized than motor symptoms, non-motor effects represent an important source of disability for many parkinsonian patients. Of these non-motor symptoms, sialorrhoea, defined as the inability to control oral secretions resulting in excessive saliva accumulation in the oropharynx, constitutes perhaps one of the most bothersome and troubling problems, often causing social embarrassment and isolation. In patients with Parkinson’s disease (PD), this symptom is thought to be due to restricted swallowing and dysfunction, rather than to hypersecretion of saliva. Only a few well designed studies have been conducted to determine the optimal treatment for sialorrhoea in PD. A combination of approaches appears to be necessary to obtain successful results.
Literature
1.
Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson’s disease: an evidence based assessment. Lancet 2002; 359: 1589–98PubMedCrossRef
2.
Gulati A, Forbes A, Stegie F, et al. A clinical observational study of the pattern and occurrence of non-motor symptoms in Parkinson’s disease ranging from early to advanced disease [abstract]. Mov Disord 2004; 19Suppl. 9: S406
3.
Visser M, Marinus J, Stiggelbout AM, et al. Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPAAUT. Mov Disord 2004; 19: 1306–12PubMedCrossRef
4.
Wüllner U, Schmitz-Hübsch T, Antony G, et al. Autonomic dysfunction in 3414 Parkinson’s disease patients enrolled in the German Network on Parkinson’s Disease (KNP e.V.): the effect of ageing. Eur J Neurol 2007 Dec; 14(12): 1405–8PubMedCrossRef
5.
6.
Manor Y, Giladi N, Cohen A, et al. Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson’s disease. Mov Disord 2007; 22: 1917–21PubMedCrossRef
7.
Leopold NA, Kagel MC. Prepharyngeal dysphagia in Parkinson’s disease. Dysphagia 1996; 11(1): 14–22PubMedCrossRef
8.
Nagler R, Hershkovich O. Relationships between age, drugs, oral sensorial complaints and salivary profile. Arch Oral Biol 2005; 50(1): 7–16PubMedCrossRef
9.
Vissink A, Spijkervet FK, Van Nieuw Amerongen A. Aging and saliva: a review of the literature. Spec Care Dent 1996; 16: 95–103CrossRef
10.
Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology 1992; 42: 726–32PubMedCrossRef
11.
Johnston BT, Li Q, Castell JA, et al. Swallowing and esophageal function in Parkinson’s disease. Am J Gastroenterol 1995; 90: 1741–6PubMed
12.
Bardow A, Nyvad B, Nauntofte B. Relationships between medication intake, complaints of dry mouth, salivary flow rate and composition, and the rate of tooth demineralization in situ. Arch Oral Biol 2001; 46: 413–23PubMedCrossRef
13.
Friedman A, Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkins Relat Disord 2001; 1: 329–32CrossRef
14.
Korcyn AD. Autonomic nervous system dysfunction in Parkinson’s disease. In: Calne DB, Crippa D, Trabucchi M, et al., editors. Parkinsonism and aging. New York: Raven Press, 1989: 211–9
15.
Martignoni E, Pacchetti C, Godi L, et al. Autonomic disorders in Parkinson’s disease. J Neural Transm 1995 Suppl. 45: 11–19
16.
Pfeiffer RF, Quigley MM. Gastrointestinal motility problems in patients with Parkinson’s disease. CNS Drugs 1999; 11: 436–48CrossRef
17.
Edwards LL, Quigley EM, Harned RK, et al. Characterization of swallowing and defecation in Parkinson’s disease. Am J Gastroenterol 1994; 89: 15–25PubMed
18.
Bagheri H, Damase-Michel C, Lapeyre-Mestre M, et al. A study of salivary secretion in Parkinson’s disease. Clin Neuropharmacol 1999: 22; 213–215PubMed
19.
Bateson MC, Gibberd FB, Wilson RS. Salivary symptoms in Parkinson disease. Arch Neurol 1973; 29(4): 274–5PubMedCrossRef
20.
Ali G, Wallace K, Schwartz R, et al. Mechanisms of oralpharyngeal dysphagia in patients with Parkinson’s disease. Gastroenterology 1996; 110: 383–92PubMedCrossRef
21.
Kalf JG, Smit AM, Bloem BR, et al. Impact of drooling in Parkinson’s disease. J Neurol 2007 Sep; 254(9): 1227–32PubMedCrossRef
22.
Chou KL, Evatt M, Hinson V, et al. Sialorrhea in Parkinson’s disease: a review. Mov Disord 2007; 22: 2306–13PubMedCrossRef
23.
Bagheri H, Damase-Michel C, Lapeyre-Mestre M, et al. A study of salivary secretion in Parkinson’s disease. Clin Neuropharmacol 1999; 22: 213–5PubMed
24.
25.
Edwards LL, Pfeiffer RF, Quigley EM, et al. Gastrointestinal symptoms in Parkinson’s disease. Mov Disord 1991; 6(2): 151–6PubMedCrossRef
26.
Eadie MJ, Tyrer JH. Alimentary disorder in Parkinsonism. Australas Ann Med 1965; 14: 13–22PubMed
27.
28.
Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. J Prosthet Dent 2001 Feb; 85(2): 162–9PubMedCrossRef
29.
Takayanagi A, Nomura T, Yamanaka S, et al. A modified device for long term sampling of parotid saliva in various experimental conditions. Bull Tokyo Dent Coll 1995; 36: 69–73PubMed
30.
Ghezzi EM, Lange LA, Ship JA. Determination of variation of stimulated salivary flow rates. J Dent Res 2000; 79: 1874–8PubMedCrossRef
31.
32.
Rothstein RD. A systematic approach to a patient with dysphagia. Hosp Pract 1997; 32: 169–75
33.
Ertekin C, Tarlaci S, Aydogdu I, et al. Electrophysiological evaluation of pharyngeal phase of swallowing in patients with Parkinson’s disease. Mov Disord 2002; 17: 942–9PubMedCrossRef
34.
Marg S, Walz B, Blenau W. The effects of dopamine receptor agonists and antagonists on the secretory rate of cockroach (Periplaneta americana) salivary glands. J Insect Physiol 2004; 50: 821–30PubMedCrossRef
35.
Koga T, Kobashi M, Mizutani M, et al. Area postrema mediates gastric motor response induced by apomorphine in rats. Brain Res 2003; 960: 122–31PubMedCrossRef
36.
Pazo JH, Belferte JE. Basal ganglia and functions of the autonomic nervous system. Cell Mol Neurobiol 2002; 22: 645–54PubMedCrossRef
37.
Pazo JH, Medina J, Tumilasci O. The role of the caudateputamen nucleus in salivary secretion induced by L-dopa. Neuropharmacology 1982; 21: 261–5PubMedCrossRef
38.
Spivak B, Adlersberg S, Rosen L, et al. Trihexyphenidyl treatment of clozapine-induced hypersalivation. Int Clin Psychopharmacol 1997; 12: 213–5PubMedCrossRef
39.
Penttilä J, Syvälahti E, Hinkka S, et al. The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system: a randomized placebo-controlled study on healthy volunteers. Psychopharmacology (Berl) 2001 Apr; 154(4): 343–9CrossRef
40.
Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson’s disease. Cochrane Database Syst Rev 2003; (1): CD003468
41.
Proulx M, de Courval FP, Wiseman MA, et al. Salivary production in Parkinson’s disease. Mov Disord 2005; 20: 204–7PubMedCrossRef
42.
Persson M, Osterberg T, Granérus AK, et al. Influence of Parkinson’s disease on oral health. Acta Odontol Scand 1992; 50: 37–42PubMedCrossRef
43.
Sockalingam S, Shammi C, Remington G. Clozapine-induced hypersalivation: a review of treatment strategies. Can J Psychiatry 2007; 52: 377–84PubMed
44.
Hori T, Makabe K, Nemoto K, et al. Hypersalivation induced by olanzapine with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 758–60PubMedCrossRef
45.
Donaldson SR. Sialorrhea as a side effect of lithium: a case report. Am J Psychiatry 1982; 139: 1350–1PubMed
46.
Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982 Jan; 11(1): 41–7PubMedCrossRef
47.
Müller T, Welnic J, Fuchs G, et al. The DONPAD study: treatment of dementia in patients with Parkinson’s disease with donepezil. J Neural Transm Suppl 2006; 71: 27–30PubMedCrossRef
48.
Freudenreich O, Herz L, Deckersbach T, et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology 2005; 181: 358–63PubMedCrossRef
49.
Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord 2005; 20Suppl. 11: S11–6PubMedCrossRef
50.
Santens P, de Noordhout AM, Belgian EODWO Study Group. Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson’s disease using a dedicated questionnaire: a Belgian multicenter survey. Acta Neurol Belg 2006 Sep; 106(3): 137–41PubMed
51.
Merello MJ, Leiguarda RC. Adynamic bowel syndrome with dramatic response to apomorphine. Clin Neuropharmacol 1994; 17: 574–8CrossRef
52.
Chauncey HH, Feller RP, Kapur KK. Longitudinal age-related changes in human parotid saliva composition. J Dent Res 1987; 66: 599–602PubMedCrossRef
53.
Tumilasci OR, Cersosimo MG, Belferte JE, et al. Quantitative study of salivary secretion in Parkinson’s disease. Mov Disord 2006; 21: 660–7PubMedCrossRef
54.
Aung W, Murata Y, Ishida R, et al. Study of quantitative oral radioactivity in salivary gland scintigraphy and determination of the clinical stage of Sjogren’s syndrome. J Nucl Med 2001; 42: 38–43PubMed
55.
Pai S, Ghezzi E, Ship J, et al. Development of a visual analogue scale questionnaire for subjective assessment of salivary dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 311–6PubMedCrossRef
56.
White KD. Salivation: a review and experimental investigation of major techniques. Psychophysiology 1977; 14: 203–12PubMedCrossRef
57.
Jones JM, Watkins CA, Hand JS, et al. Comparison of three salivary flow rate assessment methods in an elderly population. Community Dent Oral Epidemiol 2000; 28: 177–84PubMedCrossRef
58.
Jongerius PH, van Limbeek J, Rotteveel JJ. Assessment of salivary flow rate: biologic variation and measure error. Laryngoscope 2004; 114: 1801–4PubMedCrossRef
59.
Ramaker C, Marinus J, Stiggelbout AM, et al. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord 2002; 17(5): 867–76PubMedCrossRef
60.
Marks L, Turner K, O’Sullivan J, et al. Drooling in Parkinson’s disease: a novel speech and language therapy intervention. Int J Lang Commun Disord 2001; 36 Suppl.: 282–7PubMedCrossRef
61.
Thomas-Stonell N, Greenberg J. Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia 1988; 3(2): 73–8PubMedCrossRef
62.
Perez Lloret S, Piran Arce G, Rossi M, et al. Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson’s disease. Mov Disord 2007; 22: 107–11PubMedCrossRef
63.
Jongerius PH, van Tiel P, van Limbeek J, et al. A systematic review for evidence of efficacy of anticholinergic drugs to treat drooling. Arch Dis Child 2003 Oct; 88(10): 911–4PubMedCrossRef
64.
Camp-Bruno JA, Winsberg BG, Green-Parsons AR, et al. Efficacy of benztropine therapy for drooling. Dev Med Child Neurol 1989; 31: 309–19PubMedCrossRef
65.
Gillis MC, ed. Robinul product monograph. In: Compendium of Pharmaceuticals and specialties. Toronto (ON): Canadian Pharmacists Association, 1999: 1578–9
66.
Blasco PA, Stansbury JCK. Glycopyrrolate treatment of chronic drooling. Arch Pediatr Adolesc Med 1996; 150: 932–5PubMedCrossRef
67.
Blasco PA. Management of drooling: 10 years after the Consortium on Drooling, 1990. Dev Med Child Neurol 2002 Nov; 44(11): 778–81PubMedCrossRef
68.
Fox S, Thomsen T, Asante A, et al. Ipratropium bromide spray as a treatment of sialorrhea in Parkinson’s disease [abstract]. Mov Disorders 2006; 21Suppl. 15: S573
69.
Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002; 17(6): 1318–20PubMedCrossRef
70.
Heine RG, Catto-Smith AG, Reddihough DS. Effect of antireflux medication on salivary drooling in children with cerebral palsy. Dev Med Child Neurol 1996; 38: 1030–6PubMedCrossRef
71.
Newall AR, Orser R, Hunt M. The control of oral secretions in bulbar ALS/MND. J Neurol Sci 1996; 139 Suppl.: 43–4PubMedCrossRef
72.
Grabowski J. Clonidine treatment of clozapine-induced hypersalivation. J Clin Psychopharmacol 1992; 12(1): 69–70PubMedCrossRef
73.
Webber MA, Szwast SJ, Steadman TM, et al. Guanfacine treatment of Clozapine induced sialorrhea. J Clin Psychopharmacol 2004; 24(6): 675–6PubMedCrossRef
74.
Kushnir M, Eilam A, Heldman E. Modafinil reduces drooling in Parkinson’s disease. Mov Disord 2006; 21Suppl. 15: S598–9
75.
Bushara KO. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment — botulinum toxin A injections of the parotid glands. Med Hypotheses 1997; 48: 337–9PubMedCrossRef
76.
Dogu O, Apaydin D, Sevim S, et al. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin Neurol Neurosurg 2004; 106: 93–6PubMedCrossRef
77.
Lagalla G, Millevolte M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006; 21: 704–7PubMedCrossRef
78.
Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003; 61: 1279–81PubMedCrossRef
79.
Mancini F, Zangaglia R, Cristina S, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003; 18: 685–8PubMedCrossRef
80.
Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology 2004; 62: 37–40PubMedCrossRef
81.
Molloy L. Treatment of sialorrhea in patients with Parkinson’s disease: best current evidence. Curr Opin Neurol 2007; 20: 493–8PubMedCrossRef
82.
Andersen PM, Gronberg H, Franzen L, et al. External radiation of the parotid glands significantly reduces drooling in patients with motor neurone disease with bulbar paresis. J Neurol Sci 2001; 191: 111–4PubMedCrossRef
83.
Stalpers LJ, Moser EC. Results of radiotherapy for drooling in amyotrophic lateral sclerosis. Neurology 2002; 58: 1308PubMedCrossRef
84.
Borg M, Hirst F. The role of radiation therapy in the management of sialorrhea. Int J Radiat Oncol Biol Phys 1998; 41: 1113–9PubMedCrossRef
85.
Schneider AB, Lubin J, Ron E, et al. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: dose-response relationships. Radiat Res 1998; 149: 625–30PubMedCrossRef
86.
Shigematsu H, Magoshi S, Suzuki S, et al. An apparent radiation-induced carcinoma of the parotid gland following treatment for adenoid cystic carcinoma of the sublingual gland: a case report. J Oral Maxillofac Surg 2004; 62: 1169–74PubMedCrossRef
87.
Ward MJ, Levine PA. Salivary gland tumors. In: Close LG, Larson DL, Shah JP, editors. Essentials of head and neck oncology. New York: Thieme, 1998
88.
Postma AG, Heesters M, van Laar T. Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Mov Disorders 2007: 22; 2430–5CrossRef
89.
Limbrock GJ, Fischer-Brandies H, Avalle C. Castillo-Morales’ orofacial therapy: treatment of 67 children with Down syndrome. Dev Med Child Neurol 1991; 33(4): 296–303PubMedCrossRef
90.
Crysdale WS, McCann C, Roske L, et al. Saliva control issues in the neurologically challenged: a 30 year experience in team management. Int J Pediatr Otorhinolaryngol 2006; 70(3): 519–27PubMedCrossRef
91.
Marks L, Turner K, O’Sullivan J, et al. Drooling in Parkinson’s disease: a novel speech and language therapy intervention. Int J Lang Commun Disord 2001; 36 Suppl.: 282–7PubMedCrossRef
92.
Meningaud JP, Pitak-Arnnop P, Chikhani L, et al. Drooling of saliva: a review of the etiology and management options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 48–57PubMedCrossRef
93.
Grewal DS, Hiranandani NL, Rangwalla ZA, et al. Transtympanic neurectomies for control of drooling. Auris Nasus Larynx 1984; 11(2): 109–14PubMed
94.
Mullins WM, Gross CW, Moore JM. Long-term follow-up of tympanic neurectomy for sialorrhea. Laryngoscope 1979; 89(8): 1219–23PubMed
95.
Brundage SR, Moore WD. Submandibular gland resecton and bilateral parotid duct ligation as a management for chronic drooling in cerebral palsy. Plast Reconstr Surg 1989 Mar; 83(3): 443–6PubMedCrossRef
96.
Becmeur F, Horta-Geraud P, Brunot B, et al. Diversion of salivary flow to treat drooling in patients with cerebral palsy. J Pediatr Surg 1996 Dec; 31(12): 1629–33PubMedCrossRef
97.
Hamani C, Neimat J, Lozano AM. Deep brain stimulation for the treatment of Parkinson’s disease. J Neural Transm Suppl. 2006; 70: 393–9PubMedCrossRef
98.
Merello M, Starkstein S, Nouzeilles MI, et al. Bilateral pallidotomy for treatment of Parkinson’s disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation. J Neurol Neurosurg Psychiatry 2001; 71: 611–4PubMedCrossRef
99.
Ghika J, Ghika-Schmid F, Fankhauser H, et al. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson’s disease: neuropsychological and neurological side effects: report of four cases and review of the literature. J Neurosurg 1999; 91: 313–21PubMedCrossRef
100.
Merello M. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. In: Tarsy D, Okun M, Vitek J, et al., eds. Deep brain stimulation in neurological and psychiatric disorders. Totowa (NJ): Humana Press; 2008: 253–76CrossRef
101.
Serrano-Dueñas M. Sialorrhea in patients with Parkinson: a six year prospective study. Rev Neurol 2003; 37: 623–6PubMed
Metadata
Title
Sialorrhoea and Drooling in Patients with Parkinson’s Disease
Epidemiology and Management
Author
Dr Marcelo Merello
Publication date
01-12-2008
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 12/2008
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/0002512-200825120-00003

Other articles of this Issue 12/2008

Drugs & Aging 12/2008 Go to the issue

Review Article

Current Issues in Thromboprophylaxis in the Elderly

Therapy In Practice

Herpes Zoster and Postherpetic Neuralgia

Review Article

Adherence to Medication in Patients with Dementia

Review Article

Medication Withdrawal Trials in People Aged 65 Years and Older

Acknowledgments

Acknowledgement

Original Research Article

Older Patients’ Perceptions of Medication Importance and Worth
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits